- A New Drug in Practice
The FDA approval of Auvelity marks the initial steps of the drug coming to market. FDA approval means the beginning phases of testing are over, and the drug can now be prescrib… See more
Verywell Mind
Meet the newest antidepressant: dextromethorphan/buproprion
Oct 24, 2022 · Until now, dextromethorphan has been best known as a cough suppressant, and bupropion is currently FDA-approved to treat major depressive disorder and to facilitate …
Newest Antidepressants: Brexanolone, Esketamine, …
Sep 5, 2022 · In 2019, the Food and Drug Administration (FDA) approved two new antidepressants, brexanolone and esketamine. There’s also been renewed interest in agomelatine, an antidepressant not currently...
Extended-Release Antidepressant Approved for Major …
Jan 3, 2023 · Approved by the Food and Drug Administration (FDA) in August 2022 to treat MDD in adults, dextromethorphan-bupropion (Auvelity) works in a fraction of that time — as soon as after one week...
FDA Approves Rapid-Acting Oral Antidepressant
Oct 24, 2022 · The Food and Drug Administration (FDA) in August approved Auvelity—an extended-release dextromethorphan/bupropion tablet—for the treatment of major depressive disorder in adults. This combination pill is the …
Auvelity: Uses, Dosage, Side Effects & Warnings
Apr 17, 2024 · Auvelity became an FDA-approved medicine on August 18, 2022, for adults with major depressive disorder (MDD). How does Auvelity work?
FDA approves Axsome’s fast-acting treatment for …
Aug 19, 2022 · A fter a lengthy review, the Food and Drug Administration approved a fast-acting depression treatment from Axsome Therapeutics on Friday, clearing the way for the first new oral therapy for...
FDA Approves First Oral Selective 5HT1A Receptor …
Sep 29, 2023 · A new class of antidepressants has emerged, as the US Food and Drug Administration approved the first oral selective 5HT 1A receptor agonist for the treatment of major depressive disorder in adults.
U.S. FDA Approves VRAYLAR® (cariprazine) as an Adjunctive
Dec 16, 2022 · - Designed for specific mood disorders, VRAYLAR is now the first and only dopamine and serotonin partial agonist FDA-approved for the most common forms of …
Novel Oral NMDA Receptor Antagonist Approved for …
Aug 19, 2022 · The US Food and Drug Administration (FDA) has approved Auvelity (dextromethorphan HBr -bupropion HCl) extended-release tablets for the treatment of major depressive disorder (MDD) in adults, the first and only …
